Background of Sun Pharma's Generic Oxycodone Hydrochloride Approval

Sun Pharmaceutical Industries, an India-based global pharmaceutical company, received final approval from the U.S. Food and Drug Administration (FDA) on May 12, 2009, for its generic Oxycodone Hydrochloride tablets (ANDA 090659). This drug is a Mu-Opioid Receptor (OPRM1) agonist for the management of severe pain, and it demonstrated bioequivalence to the original drug, Roxicodone tablets from Mallinckrodt, upon market entry. At the time, Sun Pharma secured various dosage options ranging from 5mg to 30mg, targeting patients with acute and chronic pain. Due to the nature of generic drugs, it received approval through bioequivalence studies instead of large-scale Phase 3 clinical trials, aiming to provide a cost-effective treatment option.

Strengthening of U.S. Opioid Regulations and Product Sales Discontinuation

Currently, this product is classified as 'Discontinued' in the FDA Orange Book, meaning production and sales have ceased. This is largely due to the intensifying opioid abuse problem in the U.S., known as the 'Opioid Crisis,' which has led to unprecedented strengthening of quota regulations by the Drug Enforcement Administration (DEA) and increased oversight by the FDA. As distribution management costs and legal risks surged, Sun Pharma determined that the commercial benefits were low and voluntarily discontinued supply. This decision aligns with the trend of many generic drug developers reorganizing their portfolios to withstand lawsuits and regulatory pressures.

Restructuring of the Analgesic Market and Competitive Landscape

The global oxycodone market is estimated to be approximately $5.5 billion (approximately 7.6 trillion Korean Won) in 2025, still representing a significant market share. However, in addition to Purdue Pharma's OxyContin and Actavis, new drugs incorporating abuse-deterrent formulations (ADF) have recently dominated the market. With simple generic formulations, it is difficult to maintain price competitiveness, and alternative non-opioid analgesics and multi-target drugs are rapidly emerging, making Sun Pharma's position unsustainable. As a result, the analgesic market is being restructured towards high-value-added and proven safe formulations.

Portfolio Diversification Strategy from an Investment Perspective

Sun Pharma's discontinuation of this product is evaluated as a strategic choice to reduce reliance on high-risk analgesic pipelines and restructure its generic drug portfolio towards high-profit areas. Instead of managing traditional opioid products with high regulatory scrutiny and litigation risks, it intends to concentrate resources on specialty areas such as autoimmune diseases and anticancer drugs, which offer higher margins and less social controversy. Investors are paying close attention to Sun Pharma's efforts to overcome past concerns, such as production facility issues, and reallocate resources to develop next-generation pipelines.